INTRODUCTION: Breast cancer is one of the most common neoplasms in women and is a leading cause of cancer related deaths worldwide. Chemokines and their receptors are involved in the control of lymphocyte traffic, a critical component of systemic immunity. CXCR4 mRNA could be involved in the development of variety of diseases. Lipid peroxidation, the result of nonenzymatic autooxidation of polyunsaturated fatty acids, presents numerous harmful effects on biological systems and has been implicated in diseases like cancer. This study examined CXCR4 mRNA expression in peripheral blood cells and malondialdehyde (MDA) in plasma from blood donors and breast cancer patients. MATERIALS AND METHODS: CXCR4 expression in peripheral blood cells from 59 breast cancer patients and 76 healthy blood donors was analyzed by real-time PCR. Plasma MDA was analyzed using high-performance liquid chromatography (HPLC). CONCLUSION: In all stages, MDA levels in total breast cancer patients (1.41 +/- 0.11) were significantly higher (P < 0.01) than those in healthy subjects (0.34 +/- 0.03). No statistically significant difference occurred between CXCR4 expression in peripheral blood cells from breast cancer patients (1.69 +/- 1.05) and the normal healthy control group (1.8 +/- 0.65). However, stage II samples differed statistically (4.3 +/- 1.72) from control, total cancer patients and stages I, III and IV samples.
INTRODUCTION:Breast cancer is one of the most common neoplasms in women and is a leading cause of cancer related deaths worldwide. Chemokines and their receptors are involved in the control of lymphocyte traffic, a critical component of systemic immunity. CXCR4 mRNA could be involved in the development of variety of diseases. Lipid peroxidation, the result of nonenzymatic autooxidation of polyunsaturated fatty acids, presents numerous harmful effects on biological systems and has been implicated in diseases like cancer. This study examined CXCR4 mRNA expression in peripheral blood cells and malondialdehyde (MDA) in plasma from blood donors and breast cancerpatients. MATERIALS AND METHODS:CXCR4 expression in peripheral blood cells from 59 breast cancerpatients and 76 healthy blood donors was analyzed by real-time PCR. Plasma MDA was analyzed using high-performance liquid chromatography (HPLC). CONCLUSION: In all stages, MDA levels in total breast cancerpatients (1.41 +/- 0.11) were significantly higher (P < 0.01) than those in healthy subjects (0.34 +/- 0.03). No statistically significant difference occurred between CXCR4 expression in peripheral blood cells from breast cancerpatients (1.69 +/- 1.05) and the normal healthy control group (1.8 +/- 0.65). However, stage II samples differed statistically (4.3 +/- 1.72) from control, total cancerpatients and stages I, III and IV samples.
Authors: S A Mehta; K W Christopherson; P Bhat-Nakshatri; R J Goulet; H E Broxmeyer; L Kopelovich; H Nakshatri Journal: Oncogene Date: 2006-11-27 Impact factor: 9.867
Authors: Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: Narkunarajaa Shanmugam; James L Figarola; Yan Li; Piotr M Swiderski; Samual Rahbar; Rama Natarajan Journal: Diabetes Date: 2007-11-14 Impact factor: 9.461
Authors: Karen Brajão de Oliveira; Roberta Losi Guembarovski; Alda Maria Fiorina Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Walter Jorge Sobrinho; Carolina Batista Ariza; Maria Angelica Ehara Watanabe Journal: Clin Exp Med Date: 2012-06-15 Impact factor: 3.984
Authors: Marla Karine Amarante; Karen Brajão de Oliveira; Roberta Losi Guembarovski; Ana Cristina da Silva do Amaral Herrera; Alda Losi Guembarovski; Walter Jorge Sobrinho; Julio Cesar Voltarelli; Maria Angelica Ehara Watanabe Journal: Mol Biol Rep Date: 2012-10-11 Impact factor: 2.316
Authors: Aparecida de Lourdes Perim; Marla Karine Amarante; Roberta Losi Guembarovski; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe Journal: Cell Mol Life Sci Date: 2015-01-09 Impact factor: 9.261